AVI Ends June With $20M Cash

Luke Timmerman8/10/09

AVI Biopharma, the Bothell, WA-based developer of RNA-based therapies, said today in its quarterly financial report that it had $20.2 million in cash and investments at the end of June. The company (NASDAQ: AVII) expects to spend $10 to $12 million on operations this year, and said it anticipates it will receive more funding this year from governments and other sources.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.